1 : sarbecovirus pandemic origin understanding sarscov2 
2 : affect extent spread how factors 
3 : certificates people safe immunity will 
4 : death respiratory causes mortality cause 
5 : drugs antiviral therapeutic therapeutics vivo 
6 : fda devices immunoassays serological now 
7 : detect detecting cross-reactivity do serological 
8 : testing aki share how understanding 
9 : pandemic covid-19 march canada outbreak 
10 : reducing distancing non-pharmaceutical spread epicenter 
11 : oxygenation syndrome extracorporeal ill membrane 
12 : home closure activities school distancing 
13 : transmission virus humans asymptomatic disease 
14 : super spreaders spreader active sses 
15 : host environment droplets contaminated genetic 
16 : survive remain periods longer long 
17 : search clinicaltrialsgov registered trials we 
18 : protect community versus preventing against 
19 : soap hand alcohol-based wash sanitizer 
20 : blockers arbs risk raas ci 
21 : towns rural counties rates fatality 
22 : worse prognosis underlying cvd elevation 
23 : elderly prognosis mellitus risk underlying 
24 : prognosis risk mortality underlying outcomes 
25 : illness nlr complications severe pneumonia 
26 : symptoms atypical cough fever manifestations 
27 : develop carriers children asymptomatic unreported 
28 : benefits risks benefit-risk evidence trials 
29 : repurposable repurposed targets existing options 
30 : treating therapeutic promising effective controlled 
31 : flu seasonal spanish pandemic avian 
32 : birds do hosts reservoir humans 
33 : trials candidates being platforms currently 
34 : aki who permission certified persons 
35 : efforts future insights challenges real-time 
36 : post-fusion id pre-fusion pdb crystallized 
37 : ratg13 understand identity pangolin-cov genomic 
38 : storm pathogenesis pathogenic understanding dysregulation 
39 : storm syndrome cytokine distress storms 
40 : how do transmission locations mutations 
